# FOI 9241 - copies of documents

**FOI Request: Treatment of Lung Cancer**

**I would be grateful if you could send me all previous FOI responses from your organisation about the number of patients treated for lung cancer.**

**Please include all responses regarding lung cancer in general or specifically NSCLC (Non-Small Cell Lung Cancer) or ES-SCLC (Extensive Stage Small-Cell Lung Cancer) made from Jan 2023 to date.**

**If these documents are already in the public domain, I would be grateful if you could send me a link to their location.**

**It would be great if the information is available in CSV or Excel format, otherwise please send the PDFs.**

From a manual search of requests logged to the ‘cancer’, ‘drugs’ and ‘patient activity’ categories of the FOI database and a free-text search where lung cancer is mentioned, requests received from January 2023 to date are as follows:

**Issued April 2023**

**Freedom of Information Request: reference 8021**

**A) Over the previous 6 months, how many patients for the following diseases have been treated with a combination of Dabrafenib + Trametinib:**

**i) Metastatic Melanoma** \*Please see below

**ii) Adjuvant Melanoma** \*Please see below

**iii) BRAF mutated Lung Cancer** \*Please see below

\*Medway NHS Foundation Trust regret that we are unable to answer your request for specific diseases as this data is not collated and would only be found in individual patient records.

The Trust’s Business Intelligence department can confirm the number of patients that were diagnosed in the last six months, however, they do not record treatment details alongside this data. Please see below:

i) Metastatic Melanoma - 38

ii) Adjuvant Melanoma - Unable to provide as we do not code.

iii) BRAF mutated Lung Cancer - 147

The Trust’s Pharmacy department can advise the number of patients being treated with various drugs, however, they do not record the indication for the use of the drug. Therefore the data is for any indication, not just those requested. Under Section 21 of the Freedom of Information Act, medication under BNF Chapter 8 for Immune System and Malignant Disease is already publicly available on the Trust’s website. Please see: [https://www.medway.nhs.uk/services/medication-data.htm](https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.medway.nhs.uk%2Fservices%2Fmedication-data.htm&data=05%7C01%7Cmedwayft.foi%40nhs.net%7Cb147515daeac481e609908db4114bb5d%7C37c354b285b047f5b22207b48d774ee3%7C0%7C0%7C638175329510155511%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=JiJKit%2BVN55AjJ1cQ4YUZEjQbfUr9EM4vIAhqSnoXGo%3D&reserved=0)

**Issued June 2023**

**Freedom of Information Request: reference 8195**

**Q1 - How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:**

* **ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)**
* **Amivantamab**
* **Atezolizumab monotherapy**
* **Atezolizumab with chemotherapy**
* **Dabrafenib + Trametinib**
* **Durvalumab**
* **Gemcitabine**
* **Nitendanib + Docetaxel**
* **Nivolumab**
* **Osimertinib**
* **Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)**
* **Paclitaxel**
* **Pembrolizumab monotherapy**
* **Pembrolizumab with chemotherapy**
* **Pemetrexed with carboplatin/cisplatin**
* **RET Inhibitors (Pralsetinib, Selpercatinib)**
* **Sotorasib**
* **Tepotinib**
* **Vinorelbine monotherapy or combination with Carboplatin/Cisplatin**
* **Other active systemic anti-cancer therapy [please state]**
* **Palliative care only**

Medway NHS Foundation Trust regret that we are unable to answer your request for treatment for specific diseases as this data is not collated and would only be found in individual patient records.

The Trust’s Business Intelligence department can confirm from March-23 to May-23, a total of **56** have been treated for NSCLC, but treatment is not recorded alongside this.

The Trust’s Pharmacy department can advise the number of patients being treated with various drugs, however, they do not record the indication for the use of the drug. Therefore the data is for any indication, not just NSCLC. Under Section 21 of the Freedom of Information Act, medication under BNF Chapter 8 for Immune System and Malignant Disease is already publicly available on the Trust’s website. Please see: [https://www.medway.nhs.uk/services/medication-data.htm](https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.medway.nhs.uk%2Fservices%2Fmedication-data.htm&data=05%7C01%7Cmedwayft.foi%40nhs.net%7C06d70714bdb24d2dcded08db71648315%7C37c354b285b047f5b22207b48d774ee3%7C0%7C0%7C638228448730473025%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=gh4VKUCE7xmEnsDETWOl1I0SQuzvG0E63OrGWpjXkSw%3D&reserved=0)

**Issued: July 2023**

**Freedom of Information Request: reference 8263**

**In the past 3 months, how many early-stage (non-metastatic or Stages 1-3) Non-small cell lung cancer patients received the following treatments:**

**Atezolizumab**

**Durvalumab**

**Nivolumab**

**Pembrolizumab**

**Chemotherapy (Platinum, Taxane, Vinorelbine, Gemcitabine, Pemetrexed) only**

**Radiotherapy only**

**Chemotherapy + radiotherapy**

Medway NHS Foundation Trust regret that we are unable to answer your request as this data is not collated.

The Trust’s Business Intelligence department can confirm the number of lung cancer patients diagnosed, but we are unable to differentiate between the different types of lung cancer so have provided data held for ‘C34 – malignant neoplasm of bronchus and lung’ – 69 patients

The Trust’s Pharmacy department can advise the number of patients being treated with various drugs, however, they do not record the indication for the use of the drug. Therefore the data is for any indication, not just lung cancer. Under Section 21 of the Freedom of Information Act, medication under BNF Chapter 8 for Immune System and Malignant Disease is already publicly available on the Trust’s website. Please see: [https://www.medway.nhs.uk/services/medication-data.htm](https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.medway.nhs.uk%2Fservices%2Fmedication-data.htm&data=05%7C01%7Cmedwayft.foi%40nhs.net%7C906fc0fd81654a04c9e508db8d202a4a%7C37c354b285b047f5b22207b48d774ee3%7C0%7C0%7C638258941520612259%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=j8GWJpGINiYl9Qm0jIgxLL232JrSzH7cf4EpDrIF3cs%3D&reserved=0)

**Issued November 2023**

**Freedom of Information Request: reference 8461**

**1) Over the last 6 months, how many patients were treated with a combination of Dabrafenib + Trametinib for the following diseases:**

**A) Metastatic Melanoma**

**B) Adjuvant Melanoma**

**C) BRAF mutated Lung Cancer**

\*Please see below

**2) Over the last 6 months, how many patients were treated with a combination of Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following diseases:**

**A) Metastatic Melanoma**

**B) Colorectal Cancer**

**C) Any other indications**

\*Please see below

\*The Trust’s Pharmacy department can advise the number of patients being treated with various drugs, however, they do not record the indication for the use of the drug. Therefore the data is for any indication. Under Section 21 of the Freedom of Information Act, medication under BNF Chapter 8 for Immune System and Malignant Disease is already publicly available on the Trust’s website. Please see: [https://www.medway.nhs.uk/services/medication-data.htm](https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.medway.nhs.uk%2Fservices%2Fmedication-data.htm&data=05%7C01%7Cmedwayft.foi%40nhs.net%7Cc3c5ebb3486f4e717f9408dbe44847a6%7C37c354b285b047f5b22207b48d774ee3%7C0%7C0%7C638354771318114962%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=94L1%2Bwj2EvOEXhA3V24QMnv1AAwwBsrt6jtRjkQaghI%3D&reserved=0). Melanoma patients are treated at Maidstone and Tunbridge Wells NHS Trust.

**Issued December 2023**

**Freedom of Information Request: reference 8468**

**Q1. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:**

* **ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)**
* **Amivantamab**
* **Atezolizumab Monotherapy**
* **Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel**
* **Dabrafenib + Trametinib**
* **Docetaxel monotherapy or in combination with Carboplatin/Cisplatin**
* **Durvalumab**
* **Gemcitabine**
* **Nitedanib + Docetaxel**
* **Nivolumab**
* **Osimertinib**
* **Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)**
* **Paclitaxel**
* **Pembrolizumab Monotherapy**
* **Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)**
* **Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)**
* **Pemetrexed + Platinum (Carboplatin/Cisplatin)**
* **RET Inhibitors (Pralsetinib, Selpercatinib)**
* **Sotorasib**
* **Tepotinib**
* **Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin**
* **Other active systemic anti-cancer therapy**
* **Palliative care only**

Medway NHS Foundation Trust regret that we are unable to answer your request as this data is not collated.

The Trust’s Business Intelligence department can confirm the number that were diagnosed between July to September 2023 was 54 patients.

The Trust’s Pharmacy department can advise the number of patients being treated with various drugs, however, they do not record the indication for the use of the drug. Therefore the data is for any indication, not just NSCLC. Under Section 21 of the Freedom of Information Act, medication under BNF Chapter 8 for Immune System and Malignant Disease is already publicly available on the Trust’s website. Please see: [https://www.medway.nhs.uk/services/medication-data.htm](https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.medway.nhs.uk%2Fservices%2Fmedication-data.htm&data=05%7C01%7Cmedwayft.foi%40nhs.net%7Cc108f0847bf448bc123908dbf6563350%7C37c354b285b047f5b22207b48d774ee3%7C0%7C0%7C638374622319612955%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=4vaPKsjBUVFTIe7px7y6yGZjyZYrQSAy%2FhGlNACQQbw%3D&reserved=0)

**Q2. Of all the NSCLC patients treated with nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment with nivolumab?** This data is not collated.

**Q3. Does your trust/health board participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each active trial and the number of patients taking part.** No

**Issued February 2024**

**1) in the past 6 months, how many patients were treated with a combination of both Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following diseases:**

**A) Metastatic Melanoma**

**B) Colorectal Cancer**

**C) Any other indications**

\*Please see below

**2) In the past 6 months, how many patients were treated with a combination of Dabrafenib + Trametinib for the following diseases:**

**A) Metastatic Melanoma**

**B) Adjuvant Melanoma**

**C) BRAF mutated Lung Cancer**

\*Please see below

\*Medway NHS Foundation Trust regret that we are unable to answer your request as this data is not collated. The Trust’s Pharmacy department can advise the number of patients being treated with various drugs, however, they do not record the indication for the use of the drug. Therefore the data is for any indication, not just those at A, B and C above. Under Section 21 of the Freedom of Information Act, medication under BNF Chapter 8 for Immune System and Malignant Disease is already publicly available on the Trust’s website. Please see: [https://www.medway.nhs.uk/services/medication-data.htm](https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.medway.nhs.uk%2Fservices%2Fmedication-data.htm&data=05%7C02%7Cmedwayft.foi%40nhs.net%7Ca1e8bc33ce5048c5e8c508dc22732ff0%7C37c354b285b047f5b22207b48d774ee3%7C0%7C0%7C638423125318453176%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=%2BH5GMPyYMNgWtfUU0CdESp8h%2FFGXqfWIzHHL9MtBW50%3D&reserved=0)

**Issued April 2024**

**Freedom of Information Request: reference 8886**

**Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:**

* **CAPOX (Capecitabine with Oxaliplatin)**
* **FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)**
* **Lonsurf (Trifluridine - tipiracil)**
* **Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
* **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
* **Any other systemic anti-cancer therapy**
* **Palliative care only**

\*Please see below

**Q2. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:**

* **Atezolizumab (Tecentriq)**
* **Durvalumab (Imfinzi)**
* **Nivolumab (Opdivo)**
* **Pembrolizumab (Keytruda)**
* **Chemotherapy**
* **Radiotherapy**
* **Chemotherapy AND Radiotherapy**

\*Please see below

**Q3. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:**

* **Avelumab + Axitinib (Bavencio + Inlyta)**
* **Cabozantinib (Cometriq)**
* **Nivolumab (Opdivo)**
* **Nivolumab + Cabozantinib (Opdivo + Cometriq)**
* **Nivolumab + Ipilimumab (Opdivo + Yervoy)**
* **Pembrolizumab + Lenvatinib (Keytruda + Kisplyx)**

\*Please see below

\*Medway NHS Foundation Trust regret that we are unable to answer your request as this data is not collated.

The Trust’s Business Intelligence department can confirm the number of patients that were treated in the last three months, however, please see the notes below:

* Gastric and Gatro-Oesophageal Junction Cancer – 8
* Lung Cancer – 323 – **please note** this is looking at all lung cancers, not non-small cell in specific.
* Renal Cell Carcinoma – 104 – **please note** this is looking at all renal cell carcinomas as there is no code specifically for “advanced” renal cell carcinomas.

The Trust’s Pharmacy department can advise the number of patients being treated with various drugs, however, they do not record the indication for the use of the drug. Therefore the data is for any indication, not the cancers specifically requested. Please see attached.

**Issued April 2024**

**Freedom of Information Request: reference 8972**

**I would be grateful if you could please provide the following information with regards to patients treated with Durvalumab (Imfinzi) and Nivolumab.**

**Where the specified Nov 23 – March 24 timeframe is not possible to provide, could you please provide the latest 5 months of data you have, and specify which timeframe this covers.**

**1. How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?**

**A) Biliary Tract Cancer** 0

**B) Non-Small Cell Lung Cancer** 0

**2. How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Nivolumab for early stage (resectable) non-small cell lung cancer (Stages 1 – 3b).** <5 we are unable to confirm the stage as this is not recorded

**3. How many unique total patients were treated last month (March 24) with Durvalumab for the following indications?**

**C) Biliary Tract Cancer** 0

**D) Non-Small Cell Lung Cancer** 0

**4. How many patients received their first treatment in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?**

**E) Biliary Tract Cancer** 0

**F) Non-Small Cell Lung Cancer** 0

**Issued August 2024**

**Freedom of Information Request: reference 9105**

Thank you for your request under the Freedom of Information Act 2000.

The information you have requested is as follows:

**Q1. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:**

* **ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)**
* **Amivantamab**
* **Atezolizumab Monotherapy**
* **Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel**
* **Dabrafenib + Trametinib**
* **Docetaxel monotherapy or in combination with Carboplatin/Cisplatin**
* **Durvalumab**
* **Gemcitabine**
* **Nitedanib + Docetaxel**
* **Nivolumab**
* **Osimertinib**
* **Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)**
* **Paclitaxel**
* **Pembrolizumab Monotherapy**
* **Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)**
* **Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)**
* **Pemetrexed + Platinum (Carboplatin/Cisplatin)**
* **RET Inhibitors (Pralsetinib, Selpercatinib)**
* **Sotorasib**
* **Tepotinib**
* **Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin**
* **Other active systemic anti-cancer therapy**
* **Palliative care only**

Medway NHS Foundation Trust regret that we are unable to answer your request as this data is not collated.

The Trust’s Business Intelligence department can confirm the number of patients that were treated, however, treatment is not recorded against this data. There were 102 distinct patients seen between May and July 2024.

The Trust’s Pharmacy department can advise the number of patients being treated with various drugs, however, they do not record the indication for the use of the drug. Therefore the data is for any indication, not just NSCLC. Under Section 21 of the Freedom of Information Act, medication under BNF Chapter 8 for Immune System and Malignant Disease is already publicly available on the Trust’s website. Please see: [https://www.medway.nhs.uk/about-us/publications-and-reports/#pharmacy-data](https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.medway.nhs.uk%2Fabout-us%2Fpublications-and-reports%2F%23pharmacy-data&data=05%7C02%7Cmedwayft.foi%40nhs.net%7C230d0862126d44b54ccf08dcbba01f62%7C37c354b285b047f5b22207b48d774ee3%7C0%7C0%7C638591543604125724%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=K7mu8TC4IoOQnNG5h6cVy%2B953VtLp1eSvwGEBxDQgMg%3D&reserved=0)

**Issued August 2024**

**Freedom of Information Request: reference 9174**

**Q1. Do you treat patients for Urothelial cancer (Yes or No)? If No, where do you refer patients for treatment** Yes

**Q2. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:**

* **Atezolizumab (Tecentriq)**
* **Avelumab (Bavencio)**
* **Carboplatin single agent or in any other combination**
* **Carboplatin with Gemcitabine**
* **Carboplatin with Paclitaxel**
* **Cisplatin single agent or in any other combination**
* **Cisplatin with Gemcitabine**
* **Cisplatin with Gemcitabine + Nivolumab (Opdivo)**
* **Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)**
* **Nivolumab (Opdivo)**
* **Pembrolizumab (Keytruda)**
* **Other active systemic anti-cancer therapy**
* **Palliative care only**

Medway NHS Foundation Trust regret that we are unable to answer your request as this data is not collated.

The Trust’s Business Intelligence department can confirm the number of patients that were admitted with urothelial cancer was 146 distinct patients, however, treatment is not recorded alongside this data.

The Trust’s Pharmacy department can advise the number of patients being treated with various drugs, however, they do not record the indication for the use of the drug. Therefore the data is for any indication. Under Section 21 of the Freedom of Information Act, medication under BNF Chapter 8 for Immune System and Malignant Disease is already publicly available on the Trust’s website. Please see: [https://www.medway.nhs.uk/about-us/publications-and-reports/#pharmacy-data](https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.medway.nhs.uk%2Fabout-us%2Fpublications-and-reports%2F%23pharmacy-data&data=05%7C02%7Cmedwayft.foi%40nhs.net%7C41aedb9bd72a47f94f4808dcbd1705c4%7C37c354b285b047f5b22207b48d774ee3%7C0%7C0%7C638593153787429137%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C0%7C%7C%7C&sdata=3LdORLOohRA8GwxAW6iNrnCotIcqLf6l%2FYYDEKlwQ8o%3D&reserved=0)

**Q3. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?** No

**Q4. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:**

* **Atezolizumab (Tecentriq)**
* **Durvalumab (Imfinzi)**
* **Nivolumab (Opdivo)**
* **Pembrolizumab (Keytruda)**
* **Chemotherapy**
* **Radiotherapy**
* **Chemotherapy AND Radiotherapy**

As per question 2 above this data is not collated, however, there were 94 distinct patients admitted for NSCLC, coding does not identify whether this was for early-stage.